Relationship between previous maternal transfusions and haemolytic disease of the foetus and newborn mediated by non-RhD antibodies

Blood Transfusion

Volumn 11, Issue 4, 2013, Pages 528-532

  Dajak, Slavica ^a   Čulić, SrCrosseddsignana ^a   Stefanović, Vedran ^b   Lukačević, Jelena ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Haemolytic disease of newborn; Maternal blood transfusions; Prevention; Rbc antibodies

Indexed keywords

ERYTHROCYTE ANTIBODY; RHESUS 17 ANTIBODY; RHESUS ANTIBODY; RHESUS C ANTIBODY; RHESUS D ANTIBODY; RHESUS E ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALLOIMMUNIZATION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD GROUP KELL SYSTEM; COHORT ANALYSIS; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FETUS DISEASE; FETUS HEMOLYTIC DISEASE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; NEWBORN HEMOLYTIC DISEASE; PREGNANCY; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION;

ADULT; AGE FACTORS; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; ISOANTIBODIES; MALE; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 84891936288     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0193-12     Document Type: Article

References (22)

1. th ed. London: Blackwell Science; 2005. p. 496-545.
2. rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2002. p. 428-48.
3. Moise KJ. Fetal anemia due to non-Rhesus-D-red-cell alloimmunisation. Semin Fetal Neonatal Med 2008; 13: 207-14.
4. Nordvall M. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009; 49: 2070-5.
5. Koelewijn JM, Vrijkotte TG, van der Schoot CE, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48: 941-52.
6. Filbey D, Hanson U, Wesstrom G. The prevalence of red cell antibodies correlated to the outcome of the newborn: a 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995; 74: 687-92.
7. Dajak S, Stefanović V, Čapkun V. Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimestar screening. Transfusion 2011; 51: 1380-8.
8. Howard H, Martlew V, McFayden I, et al. Consequences for fetus and neonate of maternal red cell allo-immunisation. Arch Dis Child Fetal Neonatal Ed 1998; 78: F62-6.
9. Koelewijn J, Vrijkotte T, de Haas M, et al. Risk factors for the presence of non-Rhesus D blood cell antibodies in pregnancy. BJOG 2009; 116: 655-64.
10. Moise KJ Jr. Non-anti-D antibodies in red-cell alloimunization. Eur J Obstet Gynecol Reprod Biol 2000; 92: 75-81.
11. Caine ME, Mueller-Heubach E. Kell sensensitization in pregnancy. Am J Obstet Gynecol 1986; 154: 85-90.
12. Mayne KM, Bowell PJ, Prett GA. The significance of anti-Kell sensitization in pregnancy. Clin Lab Haematol 1990; 12: 379-85.
13. Pepperell RJ, Barrie JU, Fliegner JR. Significance of red-cell irregular antibodies in the obstetritic patient. Med J Aust 1977; ii: 453.
14. Bowell PJ, Brown SE, Dike AE. The significance of anti-c alloimunization in pregnancy. Br J Obstet Gynecol 1986; 93: 1044-8.
15. Croatian Institute for Transfusion Medicine and Croatian Institute for Health Insurance. Standards and work instructions in transfusion medicine in Croatian; 1995.
16. th ed. Betheseda: Maryland; 1993. p. 639-47.
17. th ed. W.B. Saunders company; 1992. p. 482-7.
18. th ed. W.B. Saunders company; 1996. p. 500-5.
19. th ed. W.B. Saunders company; 2000. p. 521-5.
20. th ed. W.B. Saunders company; 2003. p.601-6.
21. Hirose M, Nakanishi K, Kaku S, et al. Fetal hemolytic disease due to anti-Rh17 alloimunization. Fetal Diagn Ther 2004; 19: 182-6.
22. Li BJ, Jiang YJ, Yuan F, Ye HX. Exchange transfusion of least incompatible blood for severe hemolytic disease of the newborn due to anti-Rh17. Transfus Med 2010; 20: 66-9.